Dedicated to the discovery, development and commercialization of novel immunosuppressive therapeutics
Dr. Robert Foster
Founder & Executive Chairman
Dr. Foster has been a director and officer of Isotechnika since he founded the company in 1993. He brings to the Company expertise acquired through his education, his teaching responsibilities, and the publication of over 140 scientific papers, articles and book chapters focused on drug development and analysis. He has received numerous grants and awards for both pharmaceutical research and teaching. Additionally, Dr. Foster holds several pharmaceutical patents.
Dr. Foster was a tenured Associate Professor (clinical pharmacokinetics) in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta for a period of approximately nine years. During this time, he also served for two years as Chairman of Pharmacy Practice and numerous other university committees. He currently remains as Adjunct Full Professor in the faculty. Dr. Foster was also Medical Staff, Scientific and Research Associate in the Department of Laboratory Medicine at the Walter C. Mackenzie Health Sciences Centre from 1990 to 1994.
Dr. Foster has served on the Alberta Science and Research Authority Technology Commercialization Task Force, and was a member of the Board of Management for the Alberta Research and Science Authority. Dr. Foster also served on the Premier’s Advisory Council on Health. In addition, he has served on other companies’ Boards, is a member of numerous scientific associations, a board member of BioAlberta, on the Board of Management of Alberta Economic Development Authority and has served as a consultant with many pharmaceutical companies. He is also a member of the Institute of Corporate Directors.
Since founding the company in 1993, Dr. Foster has assembled the core scientific and business team that has led the company to its current successes. Dr. Foster, along with the other senior executive team members, has raised over $200 million through various equity financings in North America and abroad. As Founder and Executive Chairman of Isotechnika Inc., Dr. Foster and his team have taken Isotechnika Inc. to become one of Canada’s leading biotechnology companies, listed on the Toronto Stock Exchange.
Dr. Launa Aspeslet
Chief Operating Officer
Dr. Aspeslet has been with the Company since 1996 and was appointed Chief Operating Officer in January 2006. During Dr. Aspeslet’s nine years with the Company she has held numerous positions in the diagnostic, medical, and regulatory departments. Most recently, Dr. Aspeslet held the position of Senior Vice President, Regulatory Affairs where she was responsible for the overall management of investigational new drug applications and related correspondence with the United States and Canadian Health Authorities. Dr. Aspeslet also ensured that the Company followed all applicable regulations while conducting trials, and managed the quality assurance and quality control departments.
Dr. Aspeslet received her Bachelor of Science (Chemistry) degree from the University of Lethbridge in 1989. She went on to receive her Ph.D. in Pharmaceutical Sciences (Neurochemistry) from the University of Alberta in 1994. Dr. Aspeslet also received her Regulatory Affairs certification in 2000 and completed the Executive Program at the Richard Ivey School of Business in 2004.
Chief Financial Officer
Mr. Bourgeault has been the chief financial officer of the Company since 1998 and is responsible for the financial operations of the Company. Mr. Bourgeault received his Bachelor of Commerce degree from the University of Alberta in 1979 and obtained his chartered accountant designation in January 1984. Prior to joining Isotechnika Inc. he was the controller for a privately owned national distribution company from 1992 to 1998. Prior to 1992 he was a senior manager in public accounting at KPMG.
Executive Vice President and Chief Marketing Officer
Before joining Isotechnika as Executive Vice President and Chief Marketing Officer in October, 2007, Clemens Kaiser was the Chief Executive Officer of Exatec LLC (a joint venture of GE Advanced Materials and Bayer Material Science). Mr. Kaiser brings with him extensive experience in the pharmaceutical industry having held numerous executive and international leadership positions within the Bayer organization since commencing with that company in 1984.
Mr. Kaiser’s particular interest and expertise is in global markets, international business development, innovation, and the use of science and technology to develop new products and markets. As Chief Marketing Officer he oversees the global marketing, licensing and business development operations of the Company, ultimately responsible for optimizing the Company’s products within global markets. He is also responsible for identifying, conducting and concluding licensing and partnership discussions and negotiations for current and future Isotechnika compounds for all markets.
Mr. Kaiser has a degree in Business and Economics from the Free University of Berlin.
Chief Scientific Officer
Dr. Derrick Freitag has been with Isotechnika since 1996 and prior to his appointment as Chief Scientific Officer in October, 2007, Dr. Freitag held the position of Senior Director, Biopharmaceutics. Throughout his many years with the Company Dr. Freitag has also held numerous senior positions with increasing responsibilities in the drug metabolism program, the analytical chemistry laboratory and the toxicology and drug development programs. Currently Dr. Freitag is responsible to ensure that scientific resources are deployed to optimally support the Company’s drug development programs.
Dr. Freitag received his Ph.D. in Pharmaceutical Sciences, specializing in drug metabolism, from the University of Alberta in 1994. Since 2005, he has also been an Adjunct Professor with the faculty of Pharmacy and Pharmaceutical Sciences.